Physician profile
Paul D Brown
NPI 1831284405
$2,655.17
in general payments reported to CMS, 2019-2025
19 companies · $898 in 2025
The $898 reported for 2025 was more than what 83% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $301 · 2022: $398 · 2023: $463 · 2024: $595 · 2025: $898.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,956.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,956.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,241.43 | 2021-2025 | |
| Ironwood Pharmaceuticals, INC | $286.46 | 2021-2024 | Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $217.09 | 2021-2025 | Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $156.33 | 2022-2024 | Trulance, Xifaxan |
| Pfizer INC. | $133.61 | 2024-2025 | |
| Janssen Biotech, INC. | $129.40 | 2021-2025 | Tremfya |
| Ardelyx, INC. | $87.46 | 2022-2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $84.88 | 2021-2022 | |
| Celgene Corporation | $58.80 | 2023-2024 | Zeposia |
| Gilead Sciences, INC. | $46.14 | 2023-2025 | |
| Intercept Pharmaceuticals, INC. | $37.44 | 2021-2023 | Ocaliva |
| Aimmune Therapeutics, INC. | $34.71 | 2024-2025 | Zenpep |
| Genzyme Corporation | $28.91 | 2025 | |
| Bolton Medical INC | $21.74 | 2024 | Treo Abdominal Stent-Graft System |
| Organon LLC | $20.76 | 2023 | Hadlima |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $19.71 | 2025 | Wegovy |
| Lilly USA, LLC | $19.25 | 2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $17.87 | 2025 | Voquezna |
| Redhill Biopharma INC. | $13.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.